#Cardiovascular outcomes
MACE, HFpEF, CV death, the trials that move guidelines.
Retatrutide and Heart-Risk Biomarkers
A post hoc analysis of two retatrutide Phase 2 trials found large drops in atherogenic lipoproteins and CRP, not proof of fewer cardiovascular events.
Tirzepatide, blood pressure, cholesterol
A SURMOUNT post hoc analysis scores tirzepatide on all three targets at once. Between 32% and 38% of participants hit every one. Composites read differently.
Beyond weight loss: GLP-1 organ outcomes
A JACC editorial reframes GLP-1 drugs as cardiometabolic medicines. The SELECT, FLOW and SOUL trials, and the approved labels, already point that way.
Surgery vs semaglutide for heart outcomes
A large real-world study compared semaglutide with bariatric surgery on heart outcomes in obesity. Here is what it found and what it cannot prove.
Tirzepatide and heart events: BMJ study
A 2026 BMJ cohort linked tirzepatide to fewer cardiovascular events than sitagliptin, but the result remains observational.
MASLD and cardiovascular risk explained
MASLD affects 38% of adults worldwide and heart disease kills more of them than liver failure. Where semaglutide fits, and what remains unproven.
Does the eGFR dip explain heart benefit?
A 376-patient Saudi cohort asked whether the early eGFR change explains heart outcomes on dapagliflozin plus semaglutide. The answer was no.
Semaglutide and the cost of CV benefit
A 2026 cost-effectiveness review places semaglutide, a GLP-1 agonist, in the moderate tier for preventing cardiovascular events. Here is what that means.
Semaglutide and heart risk: a 2026 review
A 2026 meta-analysis of 11 trials found semaglutide cut major cardiovascular events by about a third, similarly in people with and without diabetes.